Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Comparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use.

Feger DM, Longson N, Dodanwala H, Ostrov BE, Olsen NJ, June RR.

J Clin Rheumatol. 2018 May 17. doi: 10.1097/RHU.0000000000000819. [Epub ahead of print]

PMID:
29781829
2.

Immunomodulatory interplay of the microbiome and therapy of rheumatic diseases.

Ostrov BE, Amsterdam D.

Immunol Invest. 2017 Nov;46(8):769-792. doi: 10.1080/08820139.2017.1373828.

PMID:
29058546
3.

Vaccine-Preventable Diseases Requiring Hospitalization.

Williamson G, Ahmed B, Kumar PS, Ostrov BE, Ericson JE.

Pediatrics. 2017 Sep;140(3). pii: e20170298. doi: 10.1542/peds.2017-0298. Epub 2017 Aug 2.

PMID:
28768853
4.

Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.

PMID:
28129483
5.

Terminal Ileitis as a Feature of Henoch-Schönlein Purpura Masquerading as Crohn Disease in Adults.

Sampat HN, McAllister BP, Gaines DD, Ostrov B.

J Clin Rheumatol. 2016 Mar;22(2):82-5. doi: 10.1097/RHU.0000000000000361. Review.

PMID:
26906301
6.

Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.

Ostrov BE.

Immunol Invest. 2015;44(8):777-802. doi: 10.3109/08820139.2015.1093912. Review.

PMID:
26575464
7.

Linking personality, treatment compliance.

Ostrov BF.

Mod Healthc. 2015 Jul 27;45(30):28. No abstract available.

PMID:
26510282
8.

Lyme arthritis of the pediatric lower extremity in the setting of polyarticular disease.

Aiyer A, Hennrikus W, Walrath J, Groh B, Ostrov B.

J Child Orthop. 2014 Aug;8(4):359-65. doi: 10.1007/s11832-014-0602-3. Epub 2014 Jul 23.

9.

Patient preferences and satisfaction in a multispecialty infusion center.

Ostrov BE, Reynolds K, Scalzi LV.

Patient Prefer Adherence. 2014 May 19;8:755-61. doi: 10.2147/PPA.S63214. eCollection 2014.

10.

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. doi: 10.1002/acr.22212.

11.

The interference of monoclonal antibodies with laboratory diagnosis: clinical and diagnostic implications.

Ostrov BE, Amsterdam D.

Immunol Invest. 2013;42(8):673-90. doi: 10.3109/08820139.2013.837918. Review.

PMID:
24094033
12.

Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.

Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. doi: 10.1002/acr.22088.

13.

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jul;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9.

14.

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d.

15.

Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial.

Sundel R, Solomons N, Lisk L; Aspreva Lupus Management Study (ALMS) Group.

Lupus. 2012 Nov;21(13):1433-43. doi: 10.1177/0961203312458466. Epub 2012 Aug 24.

PMID:
22922564
16.

Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group.

N Engl J Med. 2011 Nov 17;365(20):1886-95. doi: 10.1056/NEJMoa1014460.

17.

Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene.

Lin Z, Hegarty JP, Lin T, Ostrov B, Wang Y, Yu W, Kelly AA, Poritz LS, Koltun WA.

Inflamm Bowel Dis. 2011 Jun;17(6):E41-2. doi: 10.1002/ibd.21684. Epub 2011 Mar 15. No abstract available.

PMID:
21438098
18.

Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Rheumatology (Oxford). 2010 Dec;49(12):2381-90. doi: 10.1093/rheumatology/keq277. Epub 2010 Aug 27.

19.

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial.

Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group.

Arthritis Rheum. 2010 Jan;62(1):211-21. doi: 10.1002/art.25052. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

20.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group.

J Am Soc Nephrol. 2009 May;20(5):1103-12. doi: 10.1681/ASN.2008101028. Epub 2009 Apr 15.

Supplemental Content

Loading ...
Support Center